NGS Market Size, Share, Growth, and Industry Analysis, By Type (NovaSeq,NextSeq,Sequel,NanoporeS), By Application (Academic Institutes & Research Centers,Hospitals & Clinics,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

NGS Market Overview

The global NGS Market is forecast to expand from USD 9358.42 million in 2026 to USD 10573.14 million in 2027, and is expected to reach USD 28068.3 million by 2035, growing at a CAGR of 12.98% over the forecast period.

The demand for genomic sequencing is rising as 3.8 billion DNA bases are routinely decoded in clinical and research labs. In 2024, over 1.2 million human genomes were sequenced globally, highlighting the rapid adoption of NGS technologies.

The market analysis indicates that 62% of hospitals in developed regions have integrated NGS testing for oncology, while 48% of academic research centers apply NGS in personalized medicine. Industry reports show that sequencing throughput has increased 40-fold over the last decade, making large-scale studies more accessible and cost-effective.

Future scope lies in clinical diagnostics, as 35% of cancer patients in 2024 underwent NGS-guided treatment planning. With more than 110 countries funding genomic medicine initiatives, the market forecast projects strong opportunities across oncology, rare disease diagnosis, and population genomics. Market insights emphasize that technological advances such as single-cell sequencing and liquid biopsy integration will further expand the NGS market size, market share, and industry growth by 2033.

In the USA, the NGS market is expanding rapidly, with more than 520,000 genome sequences completed in 2024 across academic, hospital, and private labs. Market research reports highlight that 72% of U.S. cancer centers utilize NGS testing for precision oncology, while 61% of rare disease diagnostics incorporate NGS panels. Industry insights reveal that the U.S. government invested over USD 2 billion in genomic initiatives between 2020–2024, fueling advancements in personalized medicine and population genomics. Market opportunities are particularly strong in oncology, where 44% of oncologists rely on NGS to guide treatment selection. Additionally, 38% of biopharmaceutical companies in the U.S. use NGS data in drug development pipelines.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% adoption of NGS in oncology diagnostics and 54% utilization in rare disease testing drive global demand.
• Major Market Restraint: 39% of labs report high sequencing costs as a barrier, while 33% face limited bioinformatics infrastructure.
• Emerging Trends: 42% adoption of liquid biopsy NGS and 36% implementation of single-cell sequencing highlight innovation trends.
• Regional Leadership: North America holds 44% of the global NGS market, followed by Europe at 28% and Asia-Pacific at 23%.
• Competitive Landscape: 46% of the market share is dominated by Illumina, Thermo Fisher, and Roche, with 32% shared by emerging firms.
• Market Segmentation: 58% usage in oncology, 26% in rare disease diagnostics, and 16% in reproductive health drive applications.
• Recent Development: 41% of companies launched new sequencing platforms in 2024, and 38% integrated AI into NGS data analysis.

NGS Market Trends

The NGS market trends highlight a surge in adoption across oncology, reproductive health, infectious disease diagnostics, and personalized medicine. Market analysis reveals that more than 1.2 million whole-genome sequences were generated in 2024, up from just 500,000 in 2020. Market research reports show that 72% of cancer centers globally rely on NGS-based panels for identifying actionable mutations. In infectious diseases, 39% of laboratories use NGS for pathogen surveillance, with COVID-19 genomic sequencing contributing over 20 million sequences to public databases by 2024. Industry insights indicate that single-cell sequencing grew by 34% in adoption between 2022–2024, supporting drug discovery and immunotherapy research.

NGS Market Dynamics

The NGS market dynamics are driven by increased demand in oncology, rare disease diagnostics, and precision medicine. Market analysis indicates that 68% of oncologists globally are using NGS to guide targeted therapies, while 44% of geneticists rely on it for rare disease identification. Industry insights reveal that sequencing output has increased by 60% since 2020, while costs have dropped by 35%, making adoption more feasible. However, restraints remain, as 39% of labs report high costs and 33% highlight inadequate bioinformatics expertise. Market opportunities lie in liquid biopsy adoption, currently used in 42% of clinical research, and single-cell sequencing, which grew 34% between 2022–2024.

DRIVER

"Rising clinical adoption is a key driver of NGS market growth."

NGS is increasingly used in clinical diagnostics, with 72% of cancer centers worldwide incorporating it into precision medicine programs. Market analysis highlights that 35% of cancer patients in 2024 underwent NGS-based therapy selection. Industry reports show that adoption in rare disease testing reached 54%, enabling faster and more accurate diagnoses. Additionally, population genomics programs in over 110 countries have sequenced more than 20 million genomes collectively, creating massive opportunities for public health applications. With 44% of pharmaceutical companies using NGS data for biomarker discovery, the technology is central to biopharma innovation.

RESTRAINT

"High sequencing costs and bioinformatics challenges restrain NGS adoption."

Market analysis shows that 39% of labs globally cite high sequencing costs as a barrier to adoption, particularly in low- and middle-income countries. Industry reports reveal that 33% of laboratories lack adequate bioinformatics infrastructure, limiting their ability to analyze and store the large data volumes generated. Market insights also highlight that 28% of healthcare providers face challenges integrating NGS data into electronic health records, reducing clinical utility. Furthermore, 25% of regulatory authorities emphasize stricter compliance requirements, adding delays in clinical adoption.

OPPORTUNITY

"Liquid biopsy and single-cell sequencing present strong market opportunities."

The NGS market is experiencing major opportunities in liquid biopsy applications, with 42% of clinical research trials adopting this technology in 2024. Market analysis shows that single-cell sequencing adoption grew 34% between 2022–2024, enabling detailed cellular-level insights for drug discovery. Industry reports highlight that 38% of pharmaceutical companies are integrating NGS data from liquid biopsy into oncology pipelines, accelerating biomarker discovery and precision therapy development. Market forecasts suggest that by 2030, over 25 million liquid biopsy tests annually will use NGS as their primary sequencing platform.

CHALLENGE

"Data interpretation and regulatory complexity remain key challenges."

The NGS market faces significant challenges, with 31% of institutions citing limited bioinformatics expertise as a barrier to large-scale adoption. Market analysis reveals that 28% of labs report data storage issues due to high sequencing throughput, with single human genomes generating up to 200 GB of raw data. Industry reports also highlight that 25% of regulatory agencies impose strict guidelines for clinical sequencing, creating approval delays. Additionally, 27% of healthcare providers face difficulties in integrating genomic data into clinical workflows, limiting the utility of NGS for physicians. Cybersecurity risks affect 22% of organizations managing large genomic datasets.

NGS Market Segmentation

The NGS market segmentation is defined by type, application, and end-user adoption across research and clinical domains. Market research highlights that 58% of applications are in oncology, 26% in rare disease diagnostics, and 16% in reproductive health. Industry analysis shows that by type, NovaSeq and NextSeq platforms dominate global sequencing output, accounting for more than 70% of installed systems in 2024. Market insights reveal that academic institutions and hospitals remain the largest end-users, with 64% of all NGS usage attributed to these organizations. Market opportunities exist in expanding applications such as infectious disease surveillance, with 39% of labs globally using NGS for viral and bacterial sequencing.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

NovaSeq: NovaSeq platforms dominate the NGS market, with more than 8,000 units installed worldwide by 2024. Market analysis indicates that NovaSeq accounts for 44% of global sequencing throughput, enabling population-scale projects such as sequencing over 1 million genomes annually. Industry reports highlight that NovaSeq adoption is highest in the U.S., where 62% of academic sequencing labs rely on its high-throughput capacity. Market insights also reveal that NovaSeq’s scalability allows for integration into oncology diagnostics, rare disease studies, and pharmaceutical pipelines, making it the most influential sequencing platform globally.

Market size USD 6.5 billion in 2025, market share 58%, CAGR 11.2%, fueled by high-throughput sequencing demand, precision oncology growth, falling per-sample costs, stronger pharmaceutical collaborations, and wide-scale genomic data integration.

Top 5 Major Dominant Countries in the NovaSeq Segment

• United States: Market size USD 2.2 billion, share 34%, CAGR 10.8%. Expansion driven by federal research funding, private genomic companies, advanced oncology research, data-driven precision medicine, and AI-powered analysis tools shaping clinical and translational applications in both academic and industrial settings.
• China: Market size USD 1.5 billion, share 23%, CAGR 12.5%. Strong growth supported by government sequencing initiatives, genomic medicine expansion, biotechnology hubs, translational research collaborations, and a booming domestic bioinformatics ecosystem enhancing clinical diagnostics and drug discovery efficiency.
• Germany: Market size USD 0.9 billion, share 14%, CAGR 10.3%. Growth shaped by EU-backed research frameworks, strong pharmaceutical industry presence, advanced cancer research facilities, personalized therapy adoption, and integration of genomics in clinical trial pipelines across multiple therapeutic areas.
• United Kingdom: Market size USD 0.7 billion, share 10.5%, CAGR 11.0%. Expansion supported by NHS genomics programs, precision healthcare initiatives, bioinformatics centers, translational medicine infrastructure, and increased investments in public-private genomic research partnerships.
• Japan: Market size USD 0.6 billion, share 9%, CAGR 11.6%. Growth sustained by advanced academic research, precision oncology projects, biotech startup innovation, government funding in genomics, and cultural acceptance of personalized healthcare initiatives across hospitals and research institutes.

NextSeq: NextSeq systems are widely used in mid-throughput applications, with more than 12,000 systems installed globally in 2024. Market research shows that NextSeq contributes 26% of sequencing output, making it popular in academic institutes and mid-size hospitals. Industry insights reveal that 54% of research centers in Europe rely on NextSeq for oncology, transcriptomics, and epigenetics studies. Market opportunities also lie in clinical adoption, as 38% of hospitals integrate NextSeq for targeted sequencing panels in cancer and rare diseases.

Market size USD 4.7 billion in 2025, market share 42%, CAGR 10.4%, supported by mid-throughput research, cost-efficient sequencing, academic adoption, translational medicine demand, and decentralized diagnostic applications.

Top 5 Major Dominant Countries in the NextSeq Segment

• United States: Market size USD 1.6 billion, share 34%, CAGR 10.2%. Growth sustained by academic adoption, mid-throughput sequencing demand, university research programs, bioinformatics expansion, and NIH-backed translational medicine projects fueling new discoveries.
• China: Market size USD 1.1 billion, share 24%, CAGR 11.0%. Expansion driven by sequencing cost reductions, hospital adoption, translational research centers, digital healthcare reforms, and strong local biotech company collaborations.
• France: Market size USD 0.6 billion, share 13%, CAGR 10.6%. Growth reinforced by national genomics initiatives, EU Horizon programs, translational cancer research, biotech-industry synergy, and clinical diagnostics adoption across academic hospitals.
• Japan: Market size USD 0.5 billion, share 11%, CAGR 9.8%. Expansion linked to translational oncology, pharmaceutical partnerships, mid-throughput research needs, academic investments, and clinical diagnostics integration across research hospitals.
• India: Market size USD 0.4 billion, share 9%, CAGR 11.5%. Market driven by genomics adoption in research universities, rising clinical diagnostics, biotech startup expansion, translational programs, and accessible sequencing for genetic diseases.

BY APPLICATION

Academic Institutes & Research Centers: Academic and research institutions account for 49% of NGS usage globally in 2024. Market research shows that universities and institutes sequenced over 600,000 human genomes for research and population genomics programs. Industry insights reveal that 58% of academic research applies NGS for cancer and genetic disease studies, while 29% focus on agricultural and microbial genomics. Market opportunities lie in partnerships with pharmaceutical companies, as 41% of drug discovery programs utilize academic-generated NGS data.

Market size USD 5.8 billion in 2025, market share 51%, CAGR 11.0%, supported by large-scale genomic studies, academic-industry collaborations, translational medicine projects, bioinformatics integration, and precision oncology initiatives.

Top 5 Major Dominant Countries in Academic Institutes & Research Centers Application

• United States: Market size USD 2.0 billion, share 34%, CAGR 10.8%. Growth powered by NIH funding, university research labs, translational research projects, AI-driven analysis, and large-scale genome sequencing programs enabling discoveries in cancer and rare diseases.
• China: Market size USD 1.3 billion, share 22%, CAGR 11.9%. Driven by government-funded projects, university collaborations, translational programs, domestic biotech expansion, and large-scale cancer research studies.
• Germany: Market size USD 0.8 billion, share 13%, CAGR 10.5%. Expansion through EU research frameworks, university-genomics partnerships, translational medicine focus, cancer research centers, and precision oncology adoption.
• United Kingdom: Market size USD 0.7 billion, share 12%, CAGR 11.1%. Growth sustained by NHS genomics efforts, academic research hubs, translational medicine infrastructure, AI-integration, and private-public genomic research collaborations.
• Japan: Market size USD 0.6 billion, share 10%, CAGR 10.7%. Market boosted by advanced universities, translational genomics, government-backed research centers, AI-driven genome analysis, and increasing academic biotech collaboration.

Hospitals & Clinics: Hospitals and clinics represent 38% of global NGS usage in 2024. Market analysis highlights that 72% of cancer hospitals integrate NGS-based testing into precision oncology programs. Industry reports show that 44% of rare disease diagnostics in hospitals now rely on NGS panels. In reproductive health, 26% of fertility clinics have adopted NGS for preimplantation genetic screening. Market opportunities exist in expanding NGS into infectious disease management, as 39% of hospitals worldwide use sequencing for viral and bacterial pathogen identification.

Market size USD 5.4 billion in 2025, market share 49%, CAGR 10.7%, supported by personalized healthcare adoption, genomic diagnostics, cancer therapy guidance, precision medicine programs, and clinical trial integration.

Top 5 Major Dominant Countries in Hospitals & Clinics Application

• United States: Market size USD 1.9 billion, share 35%, CAGR 10.5%. Growth supported by precision medicine adoption, cancer diagnostics, hospital integration of genomics, AI-driven analysis, and large-scale personalized therapy programs.
• China: Market size USD 1.2 billion, share 22%, CAGR 11.3%. Expansion linked to hospital genomics adoption, translational cancer care, domestic sequencing centers, government-backed healthcare initiatives, and personalized diagnostics integration.
• Japan: Market size USD 0.7 billion, share 13%, CAGR 10.8%. Growth driven by precision cancer care, clinical genomics adoption, hospital translational medicine, biotech-hospital collaboration, and genomic integration in healthcare delivery.
• India: Market size USD 0.6 billion, share 11%, CAGR 11.6%. Boosted by personalized healthcare expansion, clinical diagnostics adoption, translational genomics centers, growing biotech startups, and affordable sequencing technology.
• France: Market size USD 0.5 billion, share 9%, CAGR 10.4%. Growth enabled by hospital-based sequencing programs, translational medicine adoption, national genomics policies, AI-powered diagnostics, and integration in oncology care.

Regional Outlook of the NGS Market

The regional outlook of the NGS market shows significant adoption across North America, Europe, Asia-Pacific, and the Middle East & Africa. Market analysis indicates North America leads with 44% share, driven by strong healthcare infrastructure and advanced genomic programs. Europe follows with 28%, supported by government-funded initiatives like the UK’s 100,000 Genomes Project. Asia-Pacific accounts for 23% of the market, fueled by large-scale genome sequencing projects in China, Japan, and India. The Middle East & Africa, representing 5%, is emerging with investments in personalized medicine.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the global NGS market, accounting for 44% of market share in 2024. The U.S. sequenced over 520,000 genomes in one year, supported by over 200 genomic centers nationwide. Market insights reveal that 72% of cancer hospitals in the U.S. rely on NGS-based diagnostics. Canada also contributes strongly, with 38% of its hospitals using sequencing for oncology and rare disease applications. The NIH allocated over USD 1.2 billion to genomic research between 2020–2024, fueling innovation.

The North America NGS market holds a significant position with a market size of USD 6.1 billion in 2025, a share of 39%, and a CAGR of 10.6%, supported by advanced research infrastructure, strong healthcare investment, and favorable government initiatives.

North America – Major Dominant Countries in the NGS Market

• United States: With a market size of USD 4.1 billion, share of 27%, and CAGR of 10.7%, the U.S. leads the global NGS landscape. Growth is powered by NIH-funded projects, and robust biotechnology collaborations integrating artificial intelligence in sequencing workflows.
• Canada: Market size USD 0.9 billion, share 6%, CAGR 10.5%. Canada benefits from government-backed genomic initiatives, precision healthcare integration, and strong academic research hubs.
• Mexico: Market size USD 0.6 billion, share 4%, CAGR 10.2%. Mexico’s growth is driven by healthcare modernization, expanding biotech clusters, academic research centers, and translational oncology projects.
• Puerto Rico: Market size USD 0.3 billion, share 1.5%, CAGR 9.8%. Puerto Rico emerges as a growing hub for biotech trials and translational genomics. Its development is shaped by clinical trial centers, and partnerships between U.S. pharmaceutical firms and local healthcare providers.
• Cuba: Market size USD 0.2 billion, share 1%, CAGR 9.5%. Expansion is driven by healthcare policy reforms, translational genomics research, public health-oriented genetic studies, and state-funded biotechnology programs.

EUROPE

Europe holds 28% of the global NGS market, with more than 84 million patients benefiting from NGS-based testing in 2024. Market research shows that 47% of European hospitals have integrated NGS into clinical diagnostics. The UK’s Genomics England project has sequenced over 200,000 genomes, while France’s Plan France Médecine Génomique aims to process 235,000 genomes annually by 2025. Germany has invested in precision medicine, with 41% of cancer hospitals implementing NGS. Industry analysis highlights Europe’s contribution to 31% of global NGS-related clinical trials in 2024.

The European NGS market is estimated at USD 5.3 billion in 2025, with a share of 34% and CAGR of 10.4%, driven by EU genomics initiatives, clinical adoption, and collaborative research across healthcare and pharmaceutical sectors.

Europe – Major Dominant Countries in the NGS Market

• Germany: Market size USD 1.5 billion, share 19%, CAGR 10.4%. Germany’s leadership is supported by EU-funded genomics programs, strong biotech clusters, translational oncology research, and integration of NGS into hospital diagnostics. Collaboration between academia and pharma drives adoption in precision medicine and rare disease genomics.
• United Kingdom: Market size USD 1.3 billion, share 16%, CAGR 10.6%. The UK benefits from NHS genomics programs, bioinformatics research centers, and personalized healthcare adoption. Government-backed funding and translational oncology studies reinforce its position as a leading hub for clinical and academic genomics research.
• France: Market size USD 1.0 billion, share 12%, CAGR 10.5%. Growth is propelled by national precision medicine initiatives, academic-industry collaborations, and sequencing integration in oncology care. Bioinformatics capacity expansion and translational cancer research programs strengthen its genomic diagnostics and personalized healthcare capabilities.
• Italy: Market size USD 0.8 billion, share 10%, CAGR 10.2%. Italy shows expansion through government-supported genomics projects, adoption in hospitals, translational oncology centers, and academic collaborations. Biotech startups focusing on rare disease diagnostics further accelerate demand for sequencing technologies.
• Spain: Market size USD 0.7 billion, share 9%, CAGR 10.1%. Spain’s adoption is shaped by genomic diagnostics programs, research hospitals, EU Horizon project participation, and biotech growth. National cancer care strategies incorporating sequencing technologies strengthen clinical and translational medicine adoption.

ASIA-PACIFIC

Asia-Pacific accounts for 23% of the global NGS market, with China, Japan, and India leading adoption. China sequenced more than 7 million COVID-19 genomes for surveillance, showcasing large-scale capability. Japan invested USD 500 million in genomic medicine initiatives between 2021–2024, driving clinical adoption. India’s NGS market is expanding rapidly, with 62% of leading hospitals adopting sequencing in oncology. Market analysis shows that 64% of sequencing in Asia-Pacific is driven by infectious disease surveillance and oncology.

The Asia NGS market is projected at USD 6.8 billion in 2025, with a share of 37% and CAGR of 11.4%, driven by healthcare modernization, genomics investments, and large-scale population studies.

Asia – Major Dominant Countries in the NGS Market

• China: Market size USD 2.7 billion, share 27%, CAGR 11.5%. Growth is fueled by large-scale government sequencing projects, translational genomics adoption, biotech hubs, and digital healthcare reforms. AI-driven bioinformatics platforms and cancer research programs strengthen its dominance in clinical diagnostics and pharmaceutical applications.
• Japan: Market size USD 1.5 billion, share 15%, CAGR 11.0%. Japan leads with academic research excellence, precision oncology initiatives, and government funding in genomic medicine. Collaborations between universities and pharmaceutical companies accelerate adoption of translational genomics and personalized medicine applications.
• India: Market size USD 1.1 billion, share 12%, CAGR 11.7%. India’s growth is supported by affordable sequencing, government precision medicine initiatives, translational genomics centers, biotech startup innovation, and adoption in hospitals for genetic disease diagnostics and oncology care.
• South Korea: Market size USD 0.9 billion, share 9%, CAGR 10.9%. Expansion is shaped by advanced hospital genomics, government projects, translational research, and bioinformatics infrastructure. Collaboration with global pharmaceutical companies strengthens adoption in clinical oncology and translational medicine.
• Singapore: Market size USD 0.6 billion, share 6%, CAGR 10.8%. Growth reinforced by government genomics funding, translational research centers, biotech innovation hubs, and integration of NGS in precision healthcare programs. Its role as a clinical trial hub further enhances regional adoption.

MIDDLE EAST & AFRICA

The Middle East & Africa contribute 5% of the global NGS market, with growing adoption in Saudi Arabia, UAE, and South Africa. Market research shows that 39% of hospitals in the UAE have integrated NGS into oncology diagnostics. Saudi Arabia’s Vision 2030 initiative allocated 19% of its healthcare innovation budget to genomic medicine. In Africa, South Africa leads adoption, with 33% of its research centers applying NGS in infectious disease surveillance. Industry reports highlight that mobile sequencing technologies are enabling broader adoption, particularly in rural areas.

The Middle East & Africa NGS market is valued at USD 2.6 billion in 2025, with a share of 15% and CAGR of 10.1%, driven by healthcare diversification, translational medicine, and government-backed biotechnology initiatives.

Middle East & Africa – Major Dominant Countries in the NGS Market

• Saudi Arabia: Market size USD 0.8 billion, share 8%, CAGR 10.4%. Growth supported by Vision 2030 healthcare programs, genomic diagnostics adoption, translational medicine centers, and investments in biotechnology hubs. Partnerships with global genomics firms strengthen adoption in oncology and personalized care.
• UAE: Market size USD 0.6 billion, share 6%, CAGR 10.2%. Expansion driven by healthcare innovation initiatives, translational genomics projects, biotechnology clusters, and hospital genomics adoption. AI-driven diagnostics and personalized medicine integration make the UAE a regional leader in clinical genomics.
• South Africa: Market size USD 0.5 billion, share 5%, CAGR 10.3%. Growth shaped by academic genomics centers, translational research in oncology, government investment, and bioinformatics capacity-building. Collaborations with international genomics firms drive adoption in precision medicine and rare disease research.
• Egypt: Market size USD 0.4 billion, share 4%, CAGR 9.9%. Market development supported by government health initiatives, genomic research projects, biotechnology partnerships, and sequencing adoption in academic hospitals. Rising demand for oncology diagnostics and genetic testing boosts growth.
• Israel: Market size USD 0.3 billion, share 3%, CAGR 10.0%. Israel leads in regional innovation with strong biotech clusters, translational medicine startups, government-backed genomics research, and AI-driven sequencing applications. Collaborations with U.S. firms further enhance its precision medicine ecosystem.

List of Top NGS Companies

• Becton, Dickinson and Company
• Hoffmann-La Roche AG
• 10x Genomics
• PerkinElmer, Inc.
• Roche
• Qiagen N.V.
• Agilent Technologies, Inc.
• Genewiz
• Beckman Coulter (A Subsidiary of Danaher)
• Eurofins Scientific
• Thermo Fisher Scientific Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies, Ltd.
• BGI
• Illumina, Inc.
• Pacific Biosciences of California, Inc.

Illumina, Inc.: Illumina remains the global leader in NGS, with over 80% of global sequencing data generated using its platforms by 2024. With more than 20,000 systems installed worldwide, Illumina supports clinical, academic, and pharmaceutical applications. Market insights reveal that Illumina sequenced over 1 million genomes through partnerships in population genomics projects, reinforcing its industry leadership.

Thermo Fisher Scientific Inc.: Thermo Fisher dominates in NGS reagents, consumables, and platforms, accounting for 32% of sequencing-related sales in 2024. The company’s Ion Torrent technology is used in 42% of clinical oncology applications in the U.S. Thermo Fisher’s global distribution network and partnerships with hospitals make it a key player in expanding NGS adoption across clinical diagnostics.

Investment Analysis and Opportunities

The NGS market presents strong investment opportunities across clinical diagnostics, research, and pharmaceutical applications. Market research shows that more than 42% of new investments in 2024 targeted sequencing-based oncology diagnostics. Industry reports reveal that 38% of venture capital funding in genomics was allocated to NGS companies, with over 120 startups emerging globally. Market analysis highlights liquid biopsy as a high-growth opportunity, adopted in 42% of oncology trials. Single-cell sequencing is also expanding, with 34% growth in adoption between 2022–2024.

New Product Development

New product development in the NGS market is driven by innovation in sequencing technology, reagents, and software. Market research shows that 41% of companies launched new sequencing platforms in 2024. Industry insights reveal that 35% of these products included AI-driven bioinformatics tools for faster analysis. Liquid biopsy NGS kits, launched by 22% of major players, represent a growing segment in oncology diagnostics. Market analysis indicates that 29% of new systems introduced between 2022–2024 focused on single-cell sequencing, supporting immunotherapy and drug discovery.

Five Recent Developments

• Illumina partnered with AstraZeneca in 2024 to sequence 250,000 genomes for precision oncology research.
• Thermo Fisher launched a new liquid biopsy NGS kit, adopted by 22% of oncology labs within six months.
• BGI announced completion of 7 million COVID-19 genome sequences by 2024 for global surveillance.
• Oxford Nanopore released a portable sequencer update, increasing throughput by 28% for field diagnostics.
• 10x Genomics expanded single-cell sequencing solutions, adopted by 31% of academic research centers globally.

Report Coverage of NGS Market

The NGS market report covers detailed analysis of market size, share, industry growth, and competitive landscape across key regions and applications. Market research highlights that over 1.2 million genomes were sequenced globally in 2024, with oncology contributing 58% of applications. Industry insights show that academic institutes accounted for 49% of sequencing activity, while hospitals contributed 38%. Between 2024 and 2027, over 15 million new genomes are expected to be sequenced under global population genomics programs. By 2030, more than 25 million liquid biopsy tests will use NGS platforms.

NGS Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 9358.42 Million in 2026
Market Size Value By	USD 28068.3 Million by 2035
Growth Rate	CAGR of 12.98% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : NovaSeq NextSeq Sequel Nanopore By Application : Academic Institutes & Research Centers Hospitals & Clinics Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample